Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, male Caucasians between 18 and 45 years of age, inclusive~* Normotensive subjects (systolic BP \<140 mmHg and diastolic BP \<90 mmHg)~* Body mass index (BMI) 19-27, minimal weight 60 kg~* Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests, and negative result in anti-ß1-receptor-autoantibody screening~* Signed Informed Consent Form~* Normal or clinically irrelevant laboratory findings~Exclusion Criteria:~* Autoimmune disorders~* Kidney diseases~* Liver diseases, liver function impairments

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- COR-1 (Type: ACTIVE_COMPARATOR): single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
- placebo (Type: PLACEBO_COMPARATOR): intravenous 0.9 % NaCl

Based on this trial design, predict the completion outcome and termination type (if applicable).